BIO applauded House of Representatives for passing bipartisan budget deal that raises discretionary budget caps, which should provide FDA with complete access to its user fees for fiscal years 2014 and 2015. Thus commending Congress, BIO President and CEO Jim Greenwood noted "the forward-thinking action" and called on House and Senate to pass both S. 1413, Pryor/Blunt FDA User Fee Protection Act, and H.R. 2725, Lance/Eshoo FDA SOS Act, to ensure FDA user fees are never again sequestered.
This story is related to the following:Trade Associations